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est anti-cancer drugs, interferons, and recombinant DNA
agents, etc.); the methodology for performing these stud-
ies generally requires separate estimations of the mean
lifetime survival (MLS) for the innovative treatment and
for the reference treatment.
METHODS: Mean survival gain (MSG), which is ex-
pressed in life-years (or months) gained per patient using
the new treatment as opposed to the other, is the differ-
ence between the two values of MLS observed with the
two treatments and is generally calculated according to
the methods of Markov or Gompertz. We have con-
ducted a literature search of studies reporting these esti-
mates of MSG.
RESULTS: The table below illustrates some values of
MSG for a series of different therapeutic problems:
CONCLUSION: The MSG can be proposed as a simple
and objective index to quantify the degree of innovation
of new treatments.
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Health-related quality of life (HRQoL) measures are in-
creasingly important for evaluating health programs and
health outcomes. Understanding the clinical and socioeco-
nomic determinants of HRQoL is a related, but relatively
little studied, topic. It is often difficult to study such rela-
tionships for large samples of individuals, because large
health survey data sets rarely include HRQoL measures.
OBJECTIVE: This paper attempts to address this prob-
lem by demonstrating the feasibility and utility of linking
algorithms for well-known quality of life indicators to
large, nationally representative databases. This process
allows the advantages of HRQoL indicators to be com-
bined with the benefits of large, nationally representative
data sets.
METHODS: We illustrate this approach using the Na-
tional Medical Expenditure Survey (NMES) and the Euro-
Qol and drawing on a previous match of the Health Util-
ity Index (HUI) with NMES. Although the NMES data
allow a good match to the EuroQol and the HUI, the
matches are not perfect. Thus we conduct sensitivity
analysis using several related specifications of each indi-
cator. We analyze the correlation of the several specifica-
tions within each set of specifications of HUI and Euro-
Qol and across the two, HUI and EuroQol.
RESULTS: By examining the within domain correlations
and the between correlations, we find that the alternate
specifications within domain are very similar and that the
two HRQoL indicators are similar in many but not all
ways. We analyze construct validity by examining the
performance of the HUI and EuroQols in empirical situa-
tions in which we have knowledge about the relation-
ships (e.g., health decreases with aging). 
CONCLUSIONS: The results suggest good construct va-
lidity.
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Cost-utility analyses conducted in phase III clinical trials
have typically obtained preference values for health out-
comes from one of two sources: direct interviews of trial
subjects, or a generic health status index to assign prefer-
ence weights to subjects. But the interview approach has
been criticized because of concerns about administrative
feasibility and generalizability. The generic instrument
approach usually requires the investigator to make sub-
jective judgments in mapping a subject’s clinical profile
into a (pre-computed) preference weight.
OBJECTIVE: This paper introduces a third approach and
tests its viability in a trial comparing rheumatoid arthritis
therapies.
METHODS: Specifically, we: (1) identified a “surrogate
sample” of arthritis patients (N  123) who were clinically
comparable to trial subjects; (2) elicited their preference
(utility) ratings for their own current (arthritis-affected)
state of health; (3) estimated a multivariable regression
model relating the surrogate-sample utility scores to these
patients’ functional status, clinical symptoms, and demo-
graphics; (4) used these regressions to assign utility scores
to trial subjects at each scheduled encounter; and (5) com-
puted encounter-specific mean utility scores for each treat-
ment group.
Disease condition Innovative treatment Standard treatment
Mean survival gain
(mo per pt)
Acute myocardial infarction TPA Streptokinase 1.08**
High-risk resected cutaneous melanoma Interferon No adjuvant therapy 15.9**
Node-positive breast cancer Adjuvant CMF No adjuvant chemotherapy 12.7**
Advanced ovarian cancer Paclitaxel 
 cisplatin Standard chemotherapy 5.2**
Hepatitis C Interferon (6 mo) No specific treatment 3.0**
Advanced pancreatic cancer Gemcitabine Fluorouracil 3.0*
*with 3% annual discounting; **with 5% annual discounting.
